ArticleMetabolic brain disease2026
Neuroprotective effects of 2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid in a rotenone-induced Parkinson's disease rat model: Modulation of oxidative stress, behavioral dysfunction, and iron accumulation.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, oxidative stress, and abnormal iron accumulation in the substantia nigra. Targeting redox imbalance and metal dysregulation represents a promising therapeutic strategy. This study evaluated the neuroprotective potential of 2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid (2,2Np-1,3TZD-4-CA) in a rotenone-induced rat model of PD. Forty-two male Sprague-Dawley rats were randomly assigned to seven experimental groups, including controls, rotenone-treated animals, compound-treated groups, and combined treatment groups. Behavioral performance was assessed using pole, inverted screen, rotarod, Y-maze, open field, and tail suspension tests. Oxidative stress markers (SOD, CAT, MDA, GSH, GPx) were measured, along with brain iron analysis and histopathological examination. Treatment with 2,2Np-1,3TZD-4-CA significantly improved rotenone-induced behavioral impairments and restored antioxidant enzyme activities (P < 0.05). Moreover, the compound reduced elevated brain iron levels and ameliorated histopathological alterations in neural tissues (P < 0.05), indicating attenuation of oxidative and metabolic damage. These findings demonstrate that 2,2Np-1,3TZD-4-CA exerts marked neuroprotective effects, likely mediated through regulation of oxidative stress and iron homeostasis, suggesting its potential therapeutic relevance for Parkinson's disease.
Indexed as
Identifiers
42384247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.